CALGARY, Alberta, Feb. 10, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that it has closed the over-subscribed private placement, initially announced on January 7, 2021, for total gross proceeds of $6.1 million (the “Offering”). In connection with the Offering, the Company issued an aggregate of 24,486,286 units (the “Units”) at a price of $0.25 per Unit.

View post:
XORTX Closes Over Subscribed Private Placement

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *